Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Pancreatic Neoplasms 3Multiple Myeloma 3Unspecified Adult Solid Tumor, Protocol Specific 2Solid Tumor 2Neoplasms 2Melanoma 2Colorectal Neoplasms 2Carcinoma, Renal Cell 2Refractory or Relapsed Solid Tumors 1Recurrence 1Prostatic Neoplasms 1Neoplasms, Plasma Cell 1Malignant Solid Tumour 1Lymphangioleiomyomatosis 1Leukemia, Myeloid, Acute 1Leukemia 1Gastrointestinal Neoplasms 1Estrogen Receptor Positive Breast Cancer 1Colonic Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Bone Metastases 1Adult Solid Neoplasm 1

Interventions

Sirolimus 2temsirolimus 1saracatinib 1Valproic Acid 1Immunoglobulin G 1Imatinib Mesylate 1Hydroxychloroquine 1Glutamine 1Disulfides 1Cetuximab 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Lymphangioleiomyomatosis × Hydroxychloroquine × Clear all
NCT01687179 2018-10-11

SAIL

Brigham and Women's Hospital

Phase 1 Completed
14 enrolled 14 charts

Lymphangioleiomyomatosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡